B. Riley Wealth Advisors Inc. Lowers Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

B. Riley Wealth Advisors Inc. lowered its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 22.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 11,412 shares of the biotechnology company’s stock after selling 3,334 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Aurinia Pharmaceuticals were worth $82,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. FMR LLC increased its position in Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Aurinia Pharmaceuticals by 10.0% during the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 4,808 shares during the period. Banque Cantonale Vaudoise raised its stake in Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after buying an additional 5,410 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Aurinia Pharmaceuticals by 13.2% during the third quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company’s stock worth $445,000 after buying an additional 7,100 shares during the period. Finally, PFG Investments LLC boosted its position in Aurinia Pharmaceuticals by 37.9% during the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 7,900 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the sale, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ:AUPH opened at $9.03 on Monday. The business’s 50-day moving average is $8.27 and its 200 day moving average is $6.90. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The firm has a market capitalization of $1.29 billion, a P/E ratio of -60.20 and a beta of 1.41.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AUPH. StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.